Ivica Horvatić

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Cardiac surgery-associated acute kidney injury: risk factors analysis and comparison of prediction models

Darko Kristović, Ivica Horvatić, Ino Husedžinović et al. · Interactive Cardiovascular and Thoracic Surgery · 2015 · 86 citations · Full text

Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome

Matija Crnogorac, Ivica Horvatić, Patricia Kaćinari et al. · Journal of Nephrology · 2017 · 59 citations

Non-diabetic renal disease in Croatian patients with type 2 diabetes mellitus

Ivica Horvatić, Miroslav Tišljar, Patricia Kaćinari et al. · Diabetes Research and Clinical Practice · 2014 · 42 citations

Croatian Patients, Urology, Renal Disease +8